`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________________
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________________
`
`ELI LILLY AND COMPANY
`Petitioner
`v.
`TEVA PHARMACEUTICALS INTERNATIONAL GMBH
`Patent Owner
`______________________
`
`IPR2018-01426
`Patent No. 9,890,211
`______________________
`
`PETITIONER’S EXHIBIT LIST AS OF AUGUST 8, 2018
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Exhibit
`Exhibit 1001 U.S. Patent No. 9,890,211
`
`Description
`
`Exhibit 1002 Reserved
`
`Exhibit 1003 Reserved
`
`Exhibit 1004 Reserved
`
`Exhibit 1005 Reserved
`
`Exhibit 1006 Reserved
`
`Exhibit 1007 Reserved
`
`Exhibit 1008 Reserved
`
`Exhibit 1009 Reserved
`
`Exhibit 1010 Reserved
`
`Exhibit 1011 Reserved
`
`Exhibit 1012 Declaration of Andrew Charles, M.D. (U.S. Patent No. 9,890,211)
`
`Exhibit 1013 Declaration of Alain P. Vasserot (U.S. Patent No. 9,890,211)
`
`Exhibit 1014 Reserved
`
`Exhibit 1015 Reserved
`
`Exhibit 1016 Reserved
`
`Exhibit 1017 Reserved
`
`Exhibit 1018 Reserved
`
`Exhibit 1019 Teva’s U.S. Provisional Application No. 60/736,623
`
`Exhibit 1020 Teva’s PCT Application No. WO 2007/054809
`
`1
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`Exhibit
`Exhibit 1021 Tan et al., “Demonstration of the Neurotransmitter Role of
`Calcitonin Gene-Related Peptides (CGRP) by Immunoblockade
`with Anti-CGRP Monoclonal Antibodies,” Br. J. Pharmacol.
`(1994) 111: 703-710
`
`Exhibit 1022 Tan et al., “Calcitonin Gene-Related Peptide as an Endogenous
`Vasodilator: Immunoblockade Studies in vivo with an Anti-
`Calcitonin Gene-Related Peptide Monoclonal Antibody and Its
`Fab’ Fragment,” Clinical Sci. (1995) 89: 565-573
`
`Exhibit 1023 Queen et al., U.S. Patent No. 6,180,370
`
`Exhibit 1024 Doods et al., “Pharmacological Profile of BIBN4096BS, the First
`Selective Small Molecule CGRP Antagonist,” Br. J. Pharmacol.
`(2000) 129: 420-423
`
`Exhibit 1025 Olesen et al., “Calcitonin Gene-Related Peptide Receptor
`Antagonist BIBN 4096 BS for the Acute Treatment of Migraine,”
`N. Engl. J. Med. (2004) 350: 1104-1110
`
`Exhibit 1026 Sveinsson, International Publication No. WO 2004/014351
`
`Exhibit 1027 Salmon et al., U.S. Patent Application Publication No. US
`2002/0162125
`
`Exhibit 1028 De Lacharriere et al., U.S. Patent No. 6,344,438
`
`Exhibit 1029 Olesen et al., “S26 CGRP Antagonism as a New Therapeutic
`Principle in Acute Migraine,” Neuropeptides (2004) 38: 110-131
`
`Exhibit 1030 Arndt et al., “CGRP Antagonism — A Valid New Concept for the
`Treatment of Migraine Pain,” Neuropeptides (2004) 38: 110-131
`
`Exhibit 1031 Arulmani et al., “Calcitonin Gene-related Peptide and Its Role in
`Migraine Pathophysiology,” Eur. J. Pharmacol. (2004) 143: 315-
`330
`
`2
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`Exhibit
`Exhibit 1032 Frobert et al., “A Sensitive Sandwich Enzyme Immunoassay for
`Calcitonin Gene-Related Peptide (CGRP): Characterization and
`Application,” Peptides (1999) 20: 275-284
`
`Exhibit 1033 Wong et al., “Monoclonal Antibody to Rat α-CGRP: Production,
`Characterization, and in vivo Immunoneutralization Activity,”
`Hybridoma (1993) 12: 93-106
`
`Exhibit 1034 Rist et al., “From Micromolar to Nanomolar Affinity: A Systematic
`Approach to Identify the Binding Site of CGRP at the Human
`Calcitonin Gene-Related Peptide 1 Receptor,” J. Med. Chem.
`(1998) 41: 117-123
`
`Exhibit 1035 Edvinsson and Hargreaves, The Headaches 289-299 (3rd ed. 2006)
`
`Exhibit 1036 Reserved
`
`Exhibit 1037 Reserved
`
`Exhibit 1038 Mason et al., “Release of the Predicted Calcitonin Gene-Related
`Peptide from Cultured Rat Trigeminal Ganglion Cells,” Nature
`(1984) 308: 653-655
`
`Exhibit 1039 Brain et al., “Calcitonin Gene-Related Peptide is a Potent
`Vasodilator,” Nature (1985) 313: 54-56
`
`Exhibit 1040 Arulmozhi et al., “Migraine: Current Concepts and Emerging
`Therapies,” Vascular Pharmacol. (2005) 43: 176-187
`
`Exhibit 1041 Durham, “CGRP-Receptor Antagonists - A Fresh Approach to
`Migraine Therapy?” N. Engl. Med. (2004) 250(11): 1073-1075
`
`Exhibit 1042
`
`Iovino et al., “Safety, Tolerability and Pharmacokinetics of BIBN
`4096 BS, the First Selective Small Molecule Calcitonin Gene-
`related Peptide Receptor Antagonist, Following Single Intravenous
`Administration in Healthy Volunteers,” Cephalalgia (2004) 24:
`645-656
`
`3
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`Exhibit
`Exhibit 1043 Goadsby et al., “Vasoactive Peptide Release in the Extracerebral
`Circulation of Humans During Migraine Headache,” Annals of
`Neurology (1990) 28(2): 183-187
`
`Exhibit 1044 Goadsby and Edvinsson, “The Trigeminovascular System and
`Migraine: Studies Characterizing Cerebrovascular and
`Neuropeptide Changes Seen in Humans and Cats,” Annals of
`Neurology (1993) 33(1): 48-56
`
`Exhibit 1045 Juhasz et al., “NO-induced Migraine Attack: Strong Increase in
`Plasma Calcitonin Gene-Related Peptide (CGRP) Concentration
`and Negative Correlation with Platelet Serotonin Release,” Pain
`(2003) 106: 461-470
`
`Exhibit 1046 Goadsby and Edvinsson, “Human in vivo Evidence for
`Trigeminovascular Activation in Cluster Headache: Neuropeptide
`Changes and Effects of Acute Attacks Therapies,” Brain (1994)
`117: 427-434
`
`Exhibit 1047 Lassen et al., “CGRP May Play a Causative Role in Migraine,”
`Cephalagia (2002) 22: 54-61
`
`Exhibit 1048 Louis et al., “Antibodies to Calcitonin-Gene Related Peptide
`Reduce Inflammation Induced by Topical Mustard Oil But Not that
`Due to Carrageenin in the Rat,” Neuroscience Letters (1989) 102:
`257-260
`
`Exhibit 1049 Dockray et al., “Immunoneutralization Studies with Calcitonin
`Gene-Related Peptide,” Annals of N.Y. Acad. Scis. (1992) 258-267
`
`Exhibit 1050 Louis et al., “The Role of Substance P and Calcitonin Gene-Related
`Peptide in Neurogenic Plasma Extravasation and Vasodilation in
`the Rat,” Neuroscience (1989) 32(3): 581-586
`
`Exhibit 1051 Sigma-Aldrich, Biochemicals & Reagents for Life Science
`Research 350-352 (2004)
`
`4
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`Exhibit
`Exhibit 1052 Escott and Brain, “Effect of a Calcitonin Gene-Related Peptide
`Antagonist (CGRP8-37) on Skin Vasodilatation and Oedema
`Induced by Stimulation of the Rat Saphenous Nerve,” Br. J.
`Pharmacol. (1993) 110: 772-776
`
`Exhibit 1053 Reserved
`
`Exhibit 1054 Reserved
`
`Exhibit 1055 Andrew et al., “Monoclonal Antibodies Distinguishing α and β
`Forms of Calcitonin Gene-Related Peptide,” J. Immunol. Methods
`(1990) 154: 87-94
`
`Exhibit 1056 Reichert et al., “Monoclonal Antibody Successes in the Clinic,”
`Nature Biotechnol. (2005) 23: 1073-1078
`
`Exhibit 1057 Projan et al., “Small Molecules for Small Minds? The Case for
`Biologic Pharmaceuticals,” Expert Opin. Biol. Ther. (2004) 4:
`1345-1350
`
`Exhibit 1058 Janeway et al., Immunobiology 93-122 (5th ed. 2001)
`
`Exhibit 1059 Janeway et al., Immunobiology 123-154 (5th ed. 2001)
`
`Exhibit 1060 Janeway et al., Immunobiology 341-380 (5th ed. 2001)
`
`Exhibit 1061 Van Valen et al., “Calcitonin Gene-Related Peptide (CGRP)
`Receptors are Linked to Cyclic Adenosine Monophosphate
`Production in SK-N-MC Human Neuroblastoma Cells,”
`Neuroscience Letters (1990) 119: 195-198
`
`Exhibit 1062 Kipriyanov and Le Gall, “Generation and Production of Engineered
`Antibodies,” Mol. Biotechnol. (2004) 26: 39-60
`
`Exhibit 1063 Elgert, Immunology: Understanding the Immune System 58-78 (1st
`ed. 1996)
`
`5
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`Exhibit
`Exhibit 1064 Wright and Morrison, “Effect of Glycosylation on Antibody
`Function: Implications for Genetic Engineering,” Trends
`Biotechnol. (1997) 15: 26-32
`
`Exhibit 1065 Brüggemann et al., “Comparison of the Effector Functions of
`Human Immunoglobulins Using a Matched Set of Chimeric
`Antibodies,” J. Exp. Med. (1987) 166: 1351-1361
`
`Exhibit 1066 Presta, “Selection, Design, and Engineering of Therapeutic
`Antibodies,” J. Allergy Clin. Immunol. (2005) 116: 731-736
`
`Exhibit 1067 Tao and Morrison, “Studies of Aglycosylated Chimeric Mouse-
`Human IgG: Role of Carbohydrate in the Structure and Effector
`Functions Mediated by the Human IgG Constant Region,” J.
`Immunol. (1989) 143: 2595-2601
`
`Exhibit 1068 Maynard and Georgiou, “Antibody Engineering,” Annu. Rev.
`Biomed. Eng. (2000) 2: 339-376
`
`Exhibit 1069 Chester and Hawkins, “Clinical Issues in Antibody Design,”
`Trends Biotechnol. (1995) 13: 294-300
`
`Exhibit 1070 Kim et al., “Antibody Engineering for the Development of
`Therapeutic Antibodies,” Mol. Cells (2005) 20: 17-29
`
`Exhibit 1071 Gavilondo and Larrick, “Antibody Engineering at the Millennium,”
`BioTechniques (2000) 29: 128-145
`
`Exhibit 1072 Khazaeli et al., “Human Immune Response to Monoclonal
`Antibodies,” J. Immunother. (1994) 15: 42-52
`
`Exhibit 1073 Carter, “Improving the Efficacy of Antibody-Based Cancer
`Therapies,” Nature Revs. Cancer (2001) 1: 118-129
`
`Exhibit 1074 Kettleborough et al., “Humanization of a Mouse Monoclonal
`Antibody by CDR-Grafting: The Importance of Framework
`Residues on Loop Conformation,” Protein Eng. (1991) 4: 773-783
`
`6
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`Exhibit
`Exhibit 1075 Queen et al., “A Humanized Antibody that Binds to the Interleukin
`2 Receptor,” Proc. Natl. Acad. Sci. USA (1989) 86: 10029-10033
`
`Exhibit 1076 Friend et al., “Phase I Study of an Engineered Aglycosylated
`Humanized CD3 Antibody in Renal Transplant Rejection,”
`Transplantation (1999) 68: 1632-1637
`
`Exhibit 1077 Brekke and Sandlie, “Therapeutic Antibodies for Human Diseases
`at the Dawn of the Twenty-First Century,” Nature Revs. Drug
`Discov. (2003) 2: 52-62
`
`Exhibit 1078 Cole et al., “Human IgG2 Variants of Chimeric Anti-CD3 are
`Nonmitogenic to T cells,” J. Immunol. (1997) 159: 3613-3621
`
`Exhibit 1079 Huse et al., International Publication No. WO 2001/27160
`
`Exhibit 1080 Reserved
`
`Exhibit 1081 Reserved
`
`Exhibit 1082 Reserved
`
`Exhibit 1083 Lisa Djavadi-Ohaniance et al., Antibody Engineering: A Practical
`Approach 77-117 (1st ed. 1996)
`
`Exhibit 1084 Van Regenmortal et al., “Improving the Quality of BIACORE-
`Based Affinity Measurements,” Dev. Biol. (Basel) (2003) 112: 141-
`151
`
`Exhibit 1085 GE Healthcare, Biacore Sensor Surface Handbook (2005)
`
`Exhibit 1086 Kelley, “Thermodynamics of Protein-Protein Interaction Studied by
`Using BIAcore and Single-Site Mutagenesis,” Methods (1994) 6:
`111-120
`
`Exhibit 1087 Johnstone et al., “The Effect of Temperature on the Binding
`Kinetics and Equilibrium Constants of Monoclonal Antibodies to
`Cell Surface Antigens,” Mol. Immunol. (1990) 27: 327-333
`
`7
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`Exhibit
`Exhibit 1088 Carter, “Potent Antibody Therapeutics by Design,” Nature Revs.
`Immunol. (2006) 6: 343-357
`
`Exhibit 1089 Goadsby et al., “Migraine — Current Understanding and
`Treatment,” N. Engl. J. Med. (2002) 346: 257-270
`
`Exhibit 1090 Petersen et al., “Inhibitory Effect of BIBN4096BS on Cephalic
`Vasodilation Induced by CGRP or Transcranial Electrical
`Stimulation in the Rat,” Br. J. Pharm. (2004) 143: 697-704
`
`Exhibit 1091 Purves et al., Neuroscience 763-773 (3rd ed. 2004)
`
`Exhibit 1092 Reserved
`
`Exhibit 1093 Reserved
`
`Exhibit 1094 Reserved
`
`Exhibit 1095 Conner et al., “Interaction of Calcitonin-Gene-Related Peptide with
`Its Receptors,” Biochemistry Society Transactions (2002) 30(4):
`451-455
`
`Exhibit 1096 Wimalawansa, “Calcitonin Gene-Related Peptide and Its
`Receptors: Molecular Genetics, Physiology, Pathophysiology, and
`Therapeutic Potentials,” Endocrine Revs. (1996) 17(5): 533-585
`
`Exhibit 1097 Williamson et al., “Intravital Microscope Studies on the Effects of
`Neurokinin Agonists and Calcitonin Gene-Related Peptide on
`Dural Vessel Diameter in the Anaesthetized Rat,” Cephalalgia
`(1997) 17: 518-524
`
`Exhibit 1098 Reserved
`
`Exhibit 1099 Reserved
`
`Exhibit 1100 Reserved
`
`Exhibit 1101 Jones et al., “Replacing the Complementarity-Determining Regions
`in a Human Antibody with Those from a Mouse,” Nature (1986)
`
`8
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`
`
`
`
`Exhibit
`
`321: 522-525
`
`Exhibit 1102 Reserved
`
`Exhibit 1103 Tysabri® Letter from the Food and Drug Administration (2004)
`
`Exhibit 1104 Pollack, “F.D.A. Approves a Multiple Sclerosis Drug,” New York
`Times (November 24, 2004)
`
`Exhibit 1105 Sandborn and Yednock, “Novel Approaches to Treating
`Inflammatory Bowel Disease: Targeting Alpha-4 Integrin,” Am. J.
`Gastroenterol (2003) 98: 2372-2382
`
`Exhibit 1106 Hamann P.R., Berger M.S. (2002) Mylotarg. In: Pagé M. (eds)
`Tumor Targeting in Cancer Therapy. Cancer Drug Discovery and
`Development. Humana Press, Totowa, NJ.
`
`Exhibit 1107 Knight et al., “Pharmacodynamic Enhancement of the Anti-Platelet
`Antibody Fab Abciximab by Site-Specific Pegylation,” Platelets
`(2004) 15: 409-418
`
`Exhibit 1108 RituxanTM (rituximab) Prescribing Information (1997)
`
`Exhibit 1109 Reff et al., “Depletion of B Cells in vivo by a Chimeric Mouse
`Human Monoclonal Antibody to CD20,” Blood (1994) 83: 435-445
`
`Exhibit 1110 Tsurushita et al., “Design of Humanized Antibodies: From anti-Tac
`to Zenapax,” Methods (2005) 36: 69-83
`
`Exhibit 1111 Simulect® (basiliximab) Prescribing Information (1998)
`
`Exhibit 1112 Synagis® (palivizumab) EMA Scientific Discussion (2004)
`
`Exhibit 1113 Wu et al., “Ultra-Potent Antibodies Against Respiratory Syncytial
`Virus: Effects of Binding Kinetics and Binding Valence on Viral
`Neutralization,” J. Mol. Biol. (2005) 350: 126-144
`
`Exhibit 1114 Maini and Feldmann, “How Does Infliximab Work in Rheumatoid
`Arthritis?” Arthritis Res. (2002) 4: S22-S28
`
`9
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`Exhibit
`Exhibit 1115 Herceptin® (trastuzumab) Prescribing Information (1998)
`
`Exhibit 1116 Carter et al., “Humanization of an Anti-p185HER2 Antibody for
`Human Cancer Therapy,” Proc. Natl. Acad. Sci. USA (1992) 89:
`4285-4289
`
`Exhibit 1117 MabCampath® (alemtuzumab) EMA Scientific Discussion (2005)
`
`Exhibit 1118 ZevalinTM (ibritumomab tiuxetan) Prescribing Information (2001)
`
`Exhibit 1119 Santora et al., “Characterization of Noncovalent Complexes of
`Recombinant Human Monoclonal Antibody and Antigen Using
`Cation Exchange, Size Exclusion Chromatography, and BIAcore,”
`Anal. Biochem. (2001) 299: 119-129
`
`Exhibit 1120 Shields et al, “Inhibition of Allergic Reactions with Antibodies to
`IgE,” Int. Arch. Allergy Immunol. (1995) 107: 308-312
`
`Exhibit 1121 Cardarelli et al., “Binding to CD20 by Anti-B1 antibody or
`F(ab')(2) is Sufficient for Induction of Apoptosis in B-Cell Lines,”
`Cancer Immunol. Immunother. (2002) 51: 15-24
`
`Exhibit 1122 Werther et al., “Humanization of an Anti-lymphocyte Function-
`Associated Antigen (LFA)-l Monoclonal Antibody and
`Reengineering of the Humanized Antibody for Binding to Rhesus
`LFA-1,” J. Immunol. (1996) 157: 4986-4995.
`
`Exhibit 1123 Goldstein et al., “Biological Efficacy of a Chimeric Antibody to the
`Epidermal Growth Factor Receptor in a Human Tumor Xenograft
`Model,” Clin. Cancer. Res. (1995) 1: 1311-1318
`
`Exhibit 1124 Avastin® (bevacizumab) EMA Scientific Discussion (2005)
`
`Exhibit 1125 Ferrara et al., “Discovery and Development of Bevacizumab, an
`Anti-VEGF Antibody for Treating Cancer,” Nature Rev. Drug
`Discov. (2004) 3: 391-400
`
`Exhibit 1126 Léger et al., “Humanization of a Mouse Antibody against Human
`
`10
`
`
`
`
`
`
`Exhibit
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`Alpha-4 Integrin: A Potential Therapeutic for the Treatment of
`Multiple Sclerosis,” Hum. Antibodies (1997) 8: 3-16
`
`Exhibit 1127 Lilly’s U.S. Provisional Application No. 60/753,004
`
`Exhibit 1128 U.S. Provisional Application No. 60/711,950
`
`Exhibit 1129 Wu et al., “Stepwise in vitro Affinity Maturation of Vitaxin, an
`αvβ3-Specific Humanized mAb,” Proc. Natl. Acad. Sci. USA (1998)
`95: 6037-42
`
`Exhibit 1130 Janeway et al., Immunobiology 626-627 (5th ed. 2001)
`
`Exhibit 1131 Reserved
`
`Exhibit 1132 Reserved
`
`Exhibit 1133 Reserved
`
`Exhibit 1134 Pisegna et al., U.S. Patent Application Publication No.
`2004/0110170
`
`Exhibit 1135 Reserved
`
`Exhibit 1136 September 5, 2013 Teva’s Response to Office Action (U.S. Patent
`No. 8,597,649 prosecution history)
`
`Exhibit 1137 Reserved
`
`Exhibit 1138 Reserved
`
`Exhibit 1139 Reserved
`
`Exhibit 1140 Reserved
`
`Exhibit 1141 Reserved
`
`Exhibit 1142 Yang et al., “CDR Walking Mutagenesis for the Affinity
`Maturation of a Potent Human Anti-HIV-1 Antibody into the
`
`11
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Exhibit
`
`Description
`Picomolar Range,” J. Mol. Biol. (1995) 254: 392-403
`
`Exhibit 1143 Reserved
`
`Exhibit 1144 Reserved
`
`Exhibit 1145 Reserved
`
`Exhibit 1146 Reserved
`
`Exhibit 1147 Reserved
`
`Exhibit 1148 Reserved
`
`Exhibit 1149 Reserved
`
`Exhibit 1150 Reserved
`
`Exhibit 1151 Reserved
`
`Exhibit 1152 Reserved
`
`Exhibit 1153 Reserved
`
`Exhibit 1154 Reserved
`
`Exhibit 1155 Reserved
`
`Exhibit 1156 Reserved
`
`Exhibit 1157 Reserved
`
`Exhibit 1158 Reserved
`
`Exhibit 1159 Reserved
`
`Exhibit 1160 Reserved
`
`Exhibit 1161 Reserved
`
`12
`
`
`
`
`
`
`Exhibit
`Exhibit 1162 Reserved
`
`Exhibit 1163 Reserved
`
`Exhibit 1164 Reserved
`
`Exhibit 1165 Reserved
`
`Exhibit 1166 Reserved
`
`Exhibit 1167 Reserved
`
`Exhibit 1168 Reserved
`
`Exhibit 1169 Reserved
`
`Exhibit 1170 Reserved
`
`Exhibit 1171 Reserved
`
`Exhibit 1172 Reserved
`
`Exhibit 1173 Reserved
`
`Exhibit 1174 Reserved
`
`Exhibit 1175 Reserved
`
`Exhibit 1176 Reserved
`
`Exhibit 1177 Reserved
`
`Exhibit 1178 Reserved
`
`Exhibit 1179 Reserved
`
`Exhibit 1180 Reserved
`
`Exhibit 1182 Reserved
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`
`13
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`
`
`
`
`Exhibit
`Exhibit 1183 Reserved
`
`Exhibit 1184 Reserved
`
`Exhibit 1185 Reserved
`
`Exhibit 1186 Reserved
`
`Exhibit 1187 Reserved
`
`Exhibit 1188 Reserved
`
`Exhibit 1189 Reserved
`
`Exhibit 1190 Reserved
`
`Exhibit 1191 Reserved
`
`Exhibit 1192 Reserved
`
`Exhibit 1193 Reserved
`
`Exhibit 1194 Reserved
`
`Exhibit 1195 Reserved
`
`Exhibit 1196 May 5, 2017 Application Data Sheet (U.S. Patent No. 9,890,211
`prosecution history)
`
`Exhibit 1197 June 26, 2017 Office Action (U.S. Patent No. 9,890,211
`prosecution history)
`
`Exhibit 1198 August 23, 2017 Teva’s Response to Office Action (U.S. Patent
`No. 9,890,211 prosecution history)
`
`Exhibit 1199 August 23, 2017 Terminal Disclaimers (U.S. Patent No. 9,890,211
`prosecution history)
`
`Exhibit 1200 May 26, 2017 Information Disclosure Statement (U.S. Patent No.
`
`14
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Exhibit
`
`Description
`9,890,211 prosecution history)
`
`Exhibit 1201 August 23, 2017 Information Disclosure Statement (U.S. Patent
`No. 9,890,211 prosecution history)
`
`Exhibit 1202 October 27, 2017 Information Disclosure Statement (U.S. Patent
`No. 9,890,211 prosecution history)
`
`
`
`
`
`
`Date: August 8, 2018
`
`
`
`Respectfully submitted,
`
`
`
`By: /William B. Raich/
`William B. Raich (Reg. No. 54,386)
`Erin M. Sommers (Reg. No. 60,974)
`Pier D. DeRoo (Reg. No. 69,340)
`Yieyie Yang (Reg. No. 71,923)
`
`Finnegan, Henderson, Farabow, Garrett &
`Dunner, L.L.P.
`901 New York Avenue, N.W.
`Washington, D.C. 20001-4413
`Telephone: 202-408-4000
`Facsimile: 202-408-4400
`
`Sanjay M. Jivraj (Reg. No. 61,806)
`Mark J. Stewart (Reg. No. 43,936)
`Eli Lilly and Company Lilly Corporate
`Center
`Indianapolis, IN 46285
`
`15
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`CERTIFICATE OF SERVICE
`Pursuant to 37 C.F.R. §§ 42.6(e) and 42.105(a), the undersigned certifies
`
`that on August 8, 2018 a copy of the foregoing Petitioner’s Exhibit List as of
`
`August 8, 2018 and Exhibits 1001, 1012-1013, 1019-1035, 1038-1052, 1055-
`
`1079, 1083-1091, 1095-1097, 1101, 1103-1130, 1134, 1136, 1142, 1196-1202
`
`were served by Priority Mail Express on the correspondence address of record
`
`indicated in the Patent Office’s public PAIR system for U.S. Patent No. 9,890,211:
`
`FISH & RICHARDSON P.C. (BO)
`P.O. Box 1022
`Minneapolis, MN 55440-1022
`
`A courtesy copy of the foregoing was also served by FedEx on the attorney
`
`
`
`for assignee Teva Pharmaceuticals International GmbH indicated in Patent Office’s
`
`public PAIR system for U.S. Patent No. 9,890,211:
`
`Elizabeth T. Karnas, Ph.D.
`FISH & RICHARDSON P.C.
`601 Lexington Avenue
`52nd Floor
`New York, NY 10022-4611
`
`
`Date: August 8, 2018
`
`
`
`
`
`
`
`
`
`
`
`By: /William Esper/
`William Esper
`Litigation Legal Assistant
`
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`
`